| Name | Title | Contact Details |
|---|
Proacta Inc. is a San Diego, CA-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Sorenson Genomics is a Salt Lake City, UT-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Bayer is a global enterprise with core competencies in the Life Science fields of health care and agriculture. Its products and services are designed to benefit people and improve their quality of life. At the same time, the Group aims to create value through innovation, growth and high earning power. Our products are helping to address some of today’s biggest challenges, including global population growth, an aging society and the need to make efficient – and, wherever possible, sustainable – use of natural resources. We are improving people’s quality of life by preventing, alleviating or curing diseases. We are helping to provide an adequate supply of high-quality food, feed and renewable plant-based raw materials. In line with our mission “Bayer: Science For A Better Life”, we aim to improve people’s quality of life. For this endeavor, we focus on our core competency of developing and successfully commercializing innovative products and solutions based on scientific knowledge.
Syner-G BioPharma Group is the premier solution provider of Chemistry, Manufacturing, and Controls (CMC) services for the life sciences industry. The company`s approach is based on CMC 360™, a fully integrated suite of CMC solutions that encompasses pharmaceutical development, regulatory affairs, and quality/cGxP compliance. The entire Syner-G organization is built around the premise of guiding small molecule, biologics, cell and gene therapy, and medical device innovators through the CMC process.
XORTX Therapeutics Inc. is a BioPharmaceutical company focused on developing innovative therapies to treat progressive kidney disease. XORTX has lead programs to develop treatments for progressive kidney disease due to diabetes, diabetic nephropathy, and polycystic kidney disease. Secondary programs focus on developing therapies for health consequences that accompany pre-diabetes, diabetes and cardiovascular disease.